3 results match your criteria: "AllerVie Health and AllerVie Clinical Research[Affiliation]"
The Impact of Prior Authorization on Clinical Practice and Patient Care Outcomes: A Work Group Report of the AAAAI Prior Authorization Task Force.
J Allergy Clin Immunol Pract
July 2024
Department of Internal Medicine, Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, Texas.
The Prior Authorization Task Force of the American Academy of Allergy, Asthma & Immunology (AAAAI), a presidential initiative of David Khan, MD, FAAAI, was established to develop an AAAAI position statement outlining ways to improve health care for our patients, to support legislation that advocates for prior authorization (PA) reform and identify the impact PA has on its membership using a questionnaire survey. This article describes the results of this survey. An electronic anonymous survey questionnaire was developed to assess the impact and burden of PA on AAAAI members and their staff and patients.
View Article and Find Full Text PDFDisease burden and predictors associated with non-response to antihistamine-based therapy in chronic spontaneous urticaria.
World Allergy Organ J
December 2023
Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, 07936, USA.
Article Synopsis
- H1-antihistamines (H1AH) are commonly used to treat chronic spontaneous urticaria (CSU), but about 50% of patients do not achieve adequate relief with standard doses.
- A study analyzed data from over 17,000 CSU patients, finding that 86.9% were classified as non-responders, who had higher rates of comorbidities and healthcare visits compared to responders.
- Factors predicting non-response included the type of treatment, the specialists patients visited, and certain health conditions like chronic pulmonary disease and depression.
Predicting Clinical Remission of Chronic Urticaria Using Random Survival Forests: Machine Learning Applied to Real-World Data.
Dermatol Ther (Heidelb)
December 2022
AllerVie Health and AllerVie Clinical Research, Birmingham, AL, USA.
Article Synopsis
- The study focuses on developing a machine learning model to predict how long it takes for patients with chronic urticaria to achieve clinical remission.
- It analyzed data from over 112,000 patients, finding that 73.5% achieved remission, typically within about 336 days.
- The model identified key factors affecting remission time, such as age, diagnosis delays, and comorbidities, and demonstrated a good performance in predictions, indicating its potential usefulness in clinical settings.